RVNC - Revance Therapeutics GAAP EPS of -$0.93 beats by $0.09 revenue of $25.95M beats by $1.22M February, 28 2022 04:30 PM Revance Therapeutics Inc. Revance Therapeutics press release (NASDAQ:RVNC): Q4 GAAP EPS of -$0.93 beats by $0.09. Revenue of $25.95M (+133.8% Y/Y) beats by $1.22M. For further details see: Revance Therapeutics GAAP EPS of -$0.93 beats by $0.09, revenue of $25.95M beats by $1.22M